The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
“…hoped we would already be able to announce the rig contract for NJOM-3 by the end of this quarter, however, we are currently at a 𝐯𝐞𝐫𝐲 𝐚𝐝𝐯𝐚𝐧𝐜𝐞𝐝 stage of negotiations on the rig contract and so we hope this will be concluded soon…”
https://www.londonstockexchange.com/news-article/TRP/interim-results-to-30-june-2023/16145203
The European Patent Office has decided against proceeding with the scheduled hearing relating to the opposition to the Company’s Immunomodulator I European patent. This follows the withdrawal of the patent opposition by a third party as announced on 19 September 2023. This favourably concludes this matter with the patent maintained as granted.
https://www.londonstockexchange.com/news-article/POLB/favourable-conclusion-of-patent-opposition/16145276
“…Battle-hardened with money in the bank and a clear plan, prospective investors should take the time to understand the company’s multi-tiered strategy, and be prepared to hold as the value of its assets are gradually unlocked, together – hopefully for all of the #BLOE stakeholders – with the value of its shares…”
https://total-market-solutions.com/2023/09/block-energy-plc-6/
Poolbeg Pharma PLC7.2p
Target Price: 19.0
Ticker: POLB
Poolbeg Pharma specialises in the development of innovative medicines to address the unmet need in infectious and other prevalent diseases. Poolbeg has a disciplined portfolio approach to mitigate risk, accelerate drug development, and enhance investor returns. The Company simultaneously advances multiple programmes in cost-effective clinical trials, rapidly generating early human safety and efficacy data to enable early partnering / out-licensing, with the funds generated reinvested in the pipeline. Poolbeg also uses AI to interrogate human challenge trial data sets to quickly identify new targets and drugs, and in-license near or in the clinic medicines, leading to faster development and greater commercial appeal. The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing pharma markets and is expected to exceed $250bn by 2025. Through opportunistic identification of assets which complement Poolbeg's existing pipeline, the Company is progressing programmes in oncology and metabolic syndromes; adding disease areas with significant addressable markets. With its initial assets from hVIVO plc (formerly Open Orphan plc), an industry leading infectious disease and human challenge trials business, Poolbeg has access to knowledge, experience, and clinical data from over 20 years of human challenge trials. The Company is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk. Amongst its portfolio of exciting assets, Poolbeg has a small molecule immunomodulator for severe influenza and other acute inflammatory conditions (POLB 001) which produces a highly significant reduction in p38 MAP kinase driven cytokines in a clinical setting; a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections (POLB 002); and a vaccine candidate for Melioidosis (POLB 003). The Company is also developing two Oral Delivery Programmes and is progressing two Artificial Intelligence (AI) Programmes to add promising new assets to its pipeline.
The #POLB CEO will be presenting at the @DDWJournal webinar on 10 October 2023
AI and Lab Automation: What are the key benefits and latest innovations?
Register here:
https://www.ddw-online.com/webinar-key-benefits-and-latest-innovations-in-ai-and-lab-automation-25862-202309/
...a little confusion here it seems.
The NEW shares have not and cannot be sold until the Company passes a resolution to increase the headroom level.
This meeting is on the 6th October.
So there should not be ANY SELLERS for next couple of weeks...
#POLB is part of this revolutionary movement with 2 successful #AI-led programs in #RSV & #Flu powered by unique human challenge trial data.
https://www.fiercebiotech.com/biotech/merck-kgaa-doubles-ai-partners-tapping-benevolentai-and-exscientia-drug-discovery-push
“…with prospects in Queensland consistently indicating prospectivity for gold and Rare Earth Elements plus a refresh of its management team, might this be the time to revisit ECR Minerals…”
https://total-market-solutions.com/2023/09/ecr-minerals-plc-2/
The #HVO VP of Clinical Operations discusses their move to #CanaryWharf:
💪How it benefits company
🤝How it benefits their clients
🏢 Current facilities status
🧪Laboratory service expansion
Watch below :
https://m.youtube.com/watch?v=ek6_v0w5XrQ&feature=youtu.be
These guys have received a notice of allowance from @JPO_JPN in relation to their Immunomodulator I patent application related to the use of p38 MAPK inhibitors for the treatment of severe #influenza. Strengthening their intellectual property protection in the territory!!
https://polaris.brighterir.com/public/poolbeg_pharma/news/rns/story/w6m9gqx
MASSIVE vote of confidence this...
All shareholders and Directors aligned and motivated to see the shareprice gain traction higher up
No fees or salaries to pay for 3 months as all directors take stock instead of salary
All directors have agreed to subscribing for shares in ECR, on the same terms as the new directors and investors to preserve cash (maybe allowing them to utilise incoming funds for working cap, new opportunities and it's existing P/f)
The new director fee is £22.5k a quarter, and the shares are intended to be issued at the end of the quarter assuming the price is above the recent placing.
After that the directors will be issued shares at the 14 day VWAP or at any new issue price during the proceeding quarter i.e a trailing price as it rises or at any further new issue price.
Shares will never be issued BELOW the initial placing price when new management came Into the company.
So all investors and new management are aligned!
Let the turnaround story begin!!!
"I’m delighted to share that the patent opposition to one of our European patents (Immunomodulator I) that was filed by a third party, is to be withdrawn. In the pharmaceutical industry it is not unusual for patents to be challenged. However, following our engagement with the opposing party, Poolbeg has reached an amicable conclusion in relation to the patent dispute without any financial compensation between the parties. This has resulted in the opposing party agreeing to withdraw its opposition to the Immunomodulator I European patent and agreeing not to challenge any of Poolbeg’s Immunomodulator I or Immunomodulator II patents in the future.This is a very favorable resolution and a positive outcome for Poolbeg, we have full confidence in the strength and validity of our patent portfolio and will continue to broaden and defend our intellectual property going forward"
Cathal Friel (Chairman and co-founder)
https://www.londonstockexchange.com/news-article/POLB/immunomodulator-i-patent-opposition-withdrawal/16129437
Congratulations to CEO, Yamin 'Mo' Khan, for being shortlisted for the #Entrepreneur of the Year Award at the @AIM_Awards 2023.
Results to be released on Thursday 12 October.
Nominations overview:
https://www.aim-awards.co.uk/nominations-overview/
You can access the #research notes directly on the Poolbeg Pharma website.
Read the research notes by @CavendishCF, @_singercm and @proactive_UK through @research_tree 💻
https://www.poolbegpharma.com/investors/analyst-research/
“…After concluding a £10m placing to fund continued exploration, and new results expected soon, is the share due another run?…”
https://total-market-solutions.com/2023/09/predator-oil-gas-holdings-plc/
The #HVO team are delighted to be attending the 9th @ESWInfluenza Conference in Valencia on 17-20 September
https://eswiconference.org/symposium/SPS01/
Does this help. This is the way i see it...
It's a purely a procedural process allowing the Company to reduce the nominal value of its shares from 1p to 0.1p WITHOUT diluting existing shareholders as the Companies Act prohibits companies from issuing shares at below the nominal value.
It'll have ZERO impact on shareholders - no new ordinary shares are being issued.
The reason for it is to allow the company to take advantage of the general authority to issue new shares (up to 20% of share capital only) it's requesting at the AGM - that means the Company is able to be more agile as and when it wants to raise some cash.
This is all subject to a shareholder vote at the AGM so is entirely in shareholder control.
There's no impact on existing warrants currently issued by the company, which have a 5p/share exercise price.
There's nothing fishy going on!
Amy more thoughts or questions please send to me and i can try and pass on to the BOD if thats helps?
david burton.tms@gmail.com
“…Elsewhere, @hVIVO_UK settled at a six-month high of 19½p, after rising 1¼p, or 6.9 per cent, as the Aim-listed drugs trial operator hailed “another period of excellent growth”
https://www.thetimes.co.uk/article/6e0736b0-518f-11ee-abb5-ce4135341f1b?shareToken=df86eb0535d704f9d7857298a95f2f39